EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors Kenji Takeuchi and Fumiaki Ito Department of
Trang 1EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors
Kenji Takeuchi and Fumiaki Ito
Department of Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan
Introduction
The epidermal growth factor receptor (EGFR) is
com-posed of an extracellular ligand-binding domain, a
transmembrane domain and an intracellular tyrosine
kinase domain The binding of a ligand to the
extracel-lular domain of the EGFR induces receptor
dimeriza-tion, activation of the intracellular kinase domain and
autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptor The tyrosine-phosphorylated motifs of the EGFR recruit various adaptors or signaling molecules [1,2] The EGFR is able to activate a variety of signaling pathways through its association with these molecules
Extra-Keywords
cancer; epidermal growth factor receptor
(EGFR); gefitinib; non-small cell lung cancer
(NSCLC); tyrosine kinase inhibitor (TKI)
Correspondence
K Takeuchi, Department of Biochemistry,
Faculty of Pharmaceutical Sciences,
Setsunan University, Hirakata, Osaka
573-0101, Japan
Fax: +81 72 866 3117
Tel: +81 72 866 3118
E-mail: takeuchi@pharm.setsunan.ac.jp
(Received 17 July 2009, revised 17
September 2009, accepted 13 October
2009)
doi:10.1111/j.1742-4658.2009.07450.x
The function of the epidermal growth factor receptor (EGFR) is dysregu-lated in various types of malignancy as a result of gene amplification, mutations, or abnormally increased ligand production Therefore, the tyro-sine kinase activity of the EGFR is a promising therapeutic target EGFR tyrosine kinase inhibitors, such as gefitinib (Iressa), show evident anticancer effects in patients with non-small cell lung cancer The induction of apop-tosis has been considered to be the major mechanism for these gefitinib-mediated anticancer effects Lung cancer cells harboring mutant EGFRs become dependent on them for their survival and, consequently, undergo apoptosis following the inhibition of EGFR tyrosine kinase by gefitinib Gefitinib has been shown to inhibit cell survival and growth signaling path-ways such as the extracellular signal-regulated kinase 1⁄ 2 pathway and the Akt pathway, as a consequence of the inactivation of EGFR However, the precise downstream signaling molecules of extracellular signal-regulated kinase 1⁄ 2 and Akt have not yet been elucidated In this minireview we have highlighted the effect of tyrosine kinase inhibitors on members of the Bcl-2 family of proteins, which are downstream signaling molecules and serve as the determinants that control apoptosis We also discuss tyrosine kinase inhibitor-induced apoptosis via c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase
Abbreviations
BH, Bcl-2 homology domain; Bim, Bcl-2 interacting mediator of cell death; CDK, cyclin-dependent kinase; CRE, cAMP-response element; CREB, CRE-binding protein; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; HNSCC, head and neck squamous cell carcinomas; IAP, inhibitor of apoptosis protein; JNK, c-Jun NH2-terminal kinase; KIP, kinase inhibitor proteins; MEK,
MAPK ⁄ ERK kinase; MKK, MAPK kinase; MKP-1, mitogen-activated protein kinase phosphatase-1; MOMP, mitochondrial outer membrane permeabilization; NSCLC, non-small cell lung cancer; Pak1, p21-activated kinase 1; PI3K, phosphatidylinositol 3-kinase; PUMA, p53
up-regulated modulator of apoptosis; RB, retinoblastoma; TKI, tyrosine kinase inhibitor.
Trang 2cellular signal-regulated kinase (ERK)1⁄ 2, which is one
of the three major groups of mitogen-activated protein
kinases (MAPKs) in mammals, is activated by the
EGFR tyrosine kinase and plays an essential role in
cell proliferation In contrast, EGFR signaling inhibits
the activation of the other two MAPKs, namely p38
MAPK and c-Jun NH2-terminal kinase (JNK)
Fur-thermore, the phosphatidylinositol 3-kinase (PI3K)⁄
Akt pathway, which is activated by the EGFR, has
been implicated in both cell proliferation and survival
Potential targets of these MAPK and PI3K⁄ Akt
sig-naling pathways include apoptosis-related molecules
(Bcl-2 family members and Fas) and cell-cycle
regula-tory molecules (e.g p27KIP1; Fig 1) The EGFR
there-fore plays an important role in both cell proliferation
and survival
EGFR function is dysregulated in various types of
malignancy [1,2] as a result of gene amplification,
mutations (resulting in a constitutively active EGFR)
or abnormally increased ligand production (reviewed
in [3]) Moreover, enforced expression of mutant
EG-FRs in transgenic mice promotes the development of
lung carcinomas [4,5] Therefore, EGFR-tyrosine
kinase is a promising therapeutic target Small
mole-cules that are active orally against the EGFR [e.g
gefitinib (Iressa) and erlotinib (Tarceva)] show evident
anticancer effects in patients with non-small cell lung
cancer (NSCLC) [6–8] Beneficial responsiveness to
these EGFR-targeting tyrosine kinase inhibitors
(TKIs) in patients with NSCLC is closely associated
with EGFR mutations such as del746-750 and L858R
in the kinase domain [9–11] Lung cancer cells
harboring mutant EGFRs become dependent on them
for their survival and, consequently, undergo
apopto-sis following inhibition of EGFR tyrosine kinase by gefitinib Gefitinib has been shown to inhibit cell growth and survival signaling pathways, such as the ERK1⁄ 2 pathway and the Akt pathway, as a conse-quence of inactivation of the EGFR [12] With refer-ence to Fig 1, which presents an overview of the intracellular signaling pathways activated by the EGFR tyrosine kinase, we will describe some of the diverse actions of TKIs on cell growth, cell survival and cell motility
target pathways for TKIs
Akt induces the phosphorylation of pro-caspase-9, thereby inhibiting its protease activity [13] Further-more, hepatocyte growth factor significantly inhibits adriamycin-induced apoptosis in the human gastric adenocarcinoma cell line MKN74 through phosphory-lation of pro-caspase-9 via the Akt signaling pathway [14] Akt also phosphorylates Bad [15], a pro-apoptotic member of the Bcl-2 family, and the forkhead tran-scription factor FKHR [16], a pro-apoptotic transcrip-tion factor Therefore, the Akt signaling pathway has emerged as the major mechanism by which growth factors promote cell survival (reviewed in [17])
A link between the Akt pathway and gefitinib-responsiveness was reported by Engelman et al [18]: the Akt pathway is down-regulated in response to gefi-tinib only in NSCLC cell lines that are growth-inhib-ited by gefitinib Thus, activated Akt has been indicated as a molecular determinant of a response to EGFR-targeting drugs However, the NSCLC cell line H3255, harboring the L858R mutation in EGFR exon
Fig 1 Major signaling pathways
downstream of the activated EGFR
Activation of several signaling cascades
triggered predominately by the ERK1⁄ 2
and the PI3K⁄ Akt pathways results, in turn,
in the inactivation of pro-apoptotic Bcl-2
proteins (e.g PUMA, Bax, Bim and Bad),
Fas, and CDK inhibitors (e.g p27 KIP1 ,
p21 WAF1 and p15 INK4b ), and also in the
activation of Pak1.
Trang 321, and PC-9, harboring a deletion (del746-750) in
EGFR exon 19, are highly sensitive to gefitinib; and
this sensitivity to gefitinib is associated with
depen-dence on both Akt and ERK1⁄ 2 pathways [10,19]
Apoptosis
The induction of apoptosis has been considered as the
major mechanism for gefitinib-mediated anticancer
effects Mammals have two distinct, but ultimately
converging, apoptosis signaling pathways: the extrinsic
(also called ‘death receptor’) pathway, which is
acti-vated by death receptors; and the intrinsic (also called
‘mitochondrial’ or ‘Bcl-2-regulated’) pathway [20] The
intrinsic pathway is characterized by the
permeabili-zation of the outer mitochondrial membrane and the
release of several pro-apoptotic factors into the
cytoplasm For mitochondrial outer membrane
per-meabilization (MOMP), a coordinated effort between
numerous Bcl-2 proteins must be engaged (reviewed in
[21]) The Bcl-2 proteins can be divided into three
groups according to their function (Fig 2) Members
of the Bcl-2 protein family are distinguished by the
presence of up to four different Bcl-2 homology
domains (designated BH1–4) The multidomain
pro-apoptotic Bcl-2 proteins, Bax and Bak, contain BH1–3
domains and only induce MOMP following apoptotic
stimuli, resulting in the release of cytochrome c,
activa-tion of the caspase cascade and cellular destrucactiva-tion
[22] To prevent cell death, Bax and Bak are bound
and inhibited by the anti-apoptotic members of the
Bcl-2 protein family (Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and
A1), which contain four BH domains [22] The third
subgroup, the BH3-only proteins, are structurally
diverse and contain only one conserved domain (BH3)
Often, the BH3-only proteins are subdivided into
direct activators [Bid and Bcl-2 interacting mediator of
cell death (Bim)] and de-repressors [Bad, Bik, Bmf,
NOXA, and p53 up-regulated modulator of apoptosis (PUMA)] These de-repressors initiate apoptosis signal-ing by bindsignal-ing and antagonizsignal-ing the anti-apoptotic Bcl-2 family members, thereby causing activation of Bax and Bak [23] Regulation of Bcl-2 family members can occur by a number of mechanisms, including up-regulation of synthesis, enhancement of degrad-ation and phosphoryldegrad-ation In the event that cancer cells undergo apoptosis in response to gefitinib, inhibi-tion of Akt- and ERK1⁄ 2-dependent pathways eventu-ally change the expression level of one or more of these Bcl-2 family members
Bad Bad is one of the ‘death-promoting’ members of the Bcl-2 family, and its pro-apoptotic activity is regulated primarily by phosphorylation at several sites [24] Acti-vated Akt [13,25] and ERK1⁄ 2-p90 ribosomal S6 kinase-1 (p90Rsk-1) [26,27] pathways have been shown
to promote survival signaling by phosphorylating Bad
at Ser136 and Ser112, respectively These phosphory-lated residues provide binding sites for 14-3-3 proteins, which subsequently sequester Bad
Phosphorylation of Bad-Ser112 via ERK1⁄ 2 path-way ( in Fig 2) is inhibited by either gefitinib or the MAPK⁄ ERK kinase (MEK) inhibitor PD98059 in mammary epithelial cells and primary cultures of malignant breast carcinoma [28] Gefitinib has no effect on EGF-mediated Bad-Ser112 phosphorylation
in the cells transfected with vectors encoding constitu-tively active p90Rsk-1 Thus, the EGF induces Bad phosphorylation through an ERK1⁄ 2 pathway involv-ing p90Rsk-1 It has also been reported that primary cultures of Bad) ⁄ )mammary cancer cells are no longer sensitive to gefitinib-induced apoptosis, suggesting that Bad might be an important pro-apoptotic effector molecule downstream of the EGFR
Fig 2 Bcl-2 family proteins as targets of TKIs.
Trang 4PUMA was initially identified as a critical mediator of
apoptosis induced by the tumor suppressor p53 [29,30]
and it can be directly activated by p53 through
p53-responsive elements in its promoter region PUMA can
also induce p53-independent apoptosis in response to a
wide variety of stimuli [31] Therefore, PUMA is a
crit-ical mediator of both p53-dependent and
p53-indepen-dent apoptosis and mediates apoptosis through the
Bcl-2 family proteins Bax⁄ Bak [32] PUMA is induced
by gefitinib, independently of p53, in head and neck
squamous cell carcinomas (HNSCC) [33] This
BH3-only protein functions as a critical mediator of
gefiti-nib-induced apoptosis, and in the Akt pathway and
p73, p53 family proteins serve as key regulators of
PUMA induction after EGFR inhibition (pathway
in Fig 2) Overexpression of EGFR is found in more
than 80% of HNSCC Thus, TKIs have emerged as
promising treatments, not only for NSCLC but also
for HNSCC
Bim
Bim is a member of the BH3-only proteins [34]
Under conditions that promote cell growth, Bim is
bound to dynein light chain (LC8) of the
microtubu-lar motor complex and is sequestered away from
other Bcl-2 family members [35] Following a
pro-apoptotic stimulus, however, Bim is localized to the
mitochondria, where it initiates the mitochondrial cell
death pathway by directly activating Bax⁄ Bak [36]
Bim expression is regulated by both transcriptional
and post-transcriptional levels (pathway in Fig 2)
Phosphorylation of Bim by ERK1⁄ 2 targets Bim for
degradation by the ubiquitin-proteasome system [37]
Bim has recently been reported to mediate
gefitinib-induced apoptosis [38–40] Bim knockdown by RNA
interference protects the NSCLC cell line, H3255,
potently against gefitinib, and the level of protection
correlates with the extent of Bim reduction, indicating
that Bim is essential for gefitinib-induced apoptosis of
NSCLC cells The induction of Bim after treatment
with gefitinib is a consequence of both transcriptional
induction and dephosphorylation Thus, shutdown of
the EGFR-MEK-ERK signaling cascade by gefitinib
elicits Bim accumulation and causes apoptosis The
T790M mutation of the EGFR, which renders
gefiti-nib and erlotigefiti-nib ineffective inhibitors of EGFR
kinase activity, blocks gefitinb-induced up-regulation
of Bim and apoptosis [38] These experiments point
to an important role for the induction of Bim in
gefitinib-triggered apoptosis of NSCLC cells
Bax Bax is a 21-kDa multi-BH domain apoptotic pro-tein and acts downstream of BH3-only propro-teins The induction of Bax expression can be sufficient to induce apoptosis and requires no additional death stimulus [41] Furthermore, Bax expression is associated with tumor development [42] The protein is normally found
in the cytoplasm, where it is heterodimerized to anti-apoptotic Bcl-2 family members such as Mcl-1 and Bcl-xL; however, once the cell is exposed to an apop-totic stimulus, Bax is translocated to the mitochondria [43] and induces mitochondrial dysfunction, character-ized by the formation of large pores in the mito-chondrial membrane [44]
Stimulation of the Akt pathway inhibits Bax translo-cation from the cytoplasm to the mitochondria and promotes survival [45] Anti-apoptotic stimuli lead to the activation of Akt and to Ser184 phosphorylation
of Bax [46] This phosphorylation promotes the seques-tration of Bax in the cytoplasm and increases the abil-ity of Bax to heterodimerize with the anti-apoptotic Bcl-2 family members Mcl-1 and Bcl-xL, thereby inhibiting activation of apoptosis signals Gefitinib is known to induce apoptosis through shutdown of Akt signaling However, it has not been demonstrated whether this shutdown transmits the apoptotic signal via inhibition of Bax phosphorylation
Regulation of Bax also occurs by mechanisms other than phosphorylation Gefitinib inhibits growth of human gallbladder adenocarcinoma cells (HAG-1) by arresting the cells in the G0⁄ G1 phase [47] This arrest
is accompanied by depression of cyclin D1 mRNA as well as by the accumulation of p27 protein However, when HAG-1 cells are treated with gefitinib for more than 72 h, the apoptotic population increases Corre-spondingly, gefitinib up-regulates expression of total Bax, with a subsequent increase in p18 Bax that has been shown to be generated through the cleavage of full-length Bax during apoptosis (pathway in Fig 2) Cleavage of Bax into p18 Bax occurs in response to various stimuli, such as interferon-a [48] and chemo-therapeutic agents [49] p18 Bax fragment is as efficient
as full-length Bax in promoting cytochrome c release [49,50] and more potent than full-length Bax in induc-ing apoptotic cell death [51] It is also suggested that
an increase in gefitinib-induced expression of total Bax
is caused by the decreased degradation of Bax As ERK1⁄ 2 and Akt are significantly inhibited in gefiti-nib-treated HAG-1 cells, simultaneous inhibition of these pathways by gefitinib may lead to the accumula-tion of Bax and subsequent apoptosis As described below, gefitinib initiates the intrinsic pathway of
Trang 5apop-tosis through p38a-dependent Bax activation in
intesti-nal epithelial cells (pathway in Fig 2) Accordingly,
inhibition of Akt-dependent Bax phosphorylation at
Ser184, generation of the p18 Bax fragment and
p38a-dependent Bax activation are proposed for Bax
activation Further studies are needed to understand
the precise mechanism by which gefitinib induces
apoptosis in a Bax-dependent manner
Inhibitor of apoptosis protein family
Induction of MOMP following apoptotic stimuli
results in the release of cytochrome c and subsequent
activation of caspase-9 and caspase-3, which are
cystein proteases that cleave vital cellular targets and
cause apoptosis Caspases can be inhibited by members
of the inhibitor of apoptosis protein (IAP) family such
as cIAP-1, cIAP-2, X-linked IAP and survivin Recent
studies have suggested that activation of the PI3K⁄ Akt
pathway by EGFR signaling causes up-regulation of
survivin expression [52] The levels of cIAP-2 are
down-regulated by gefitinib or erlotinib in intestinal
epithelial cells [53] Furthermore, the expression of
cIAP-1 and of X-linked IAP is reduced by AG1478 in
squamous cell carcinoma cell lines NA and Ca9-22
[54] As small interfering RNA (siRNA)-based
deple-tion of IAP increases apoptosis in response to gefitinib,
IAPs might be a molecular target for the induction of
apoptosis by TKIs
Inhibition of cell proliferation
EGFR signaling activates a variety of pathways such
as those for cell survival, cell proliferation, cell
motil-ity, angiogenesis and expression of extracellular matrix
proteins [55] Accordingly, TKIs against EGFR exert
not only apoptosis-inducing action but also other
divergent actions For instance, EGFR inhibition leads
to the induction of cell-cycle arrest at the G1-S bound-ary [56] Cell-cycle regulation is important in growth control, and therefore deregulation of the cell-cycle machinery has been implicated in carcinogenesis [57] Cyclins and cyclin-dependent kinases (CDKs), in asso-ciation with each other, play key roles in promoting the G1-to-S phase transition of the cell-cycle by phos-phorylating the retinoblastoma (RB) protein Activa-tion of cyclin–CDK complexes is counterbalanced by CDK inhibitors, including those of the kinase inhibitor proteins (KIP) family and the INK4 family (Fig 3) The KIP family consists of p27KIP1, p21WAF1⁄ CIP1and p57KIP2; and the INK4 family consists of p15INK4b, p16INK4a, p18INK4cand p19INK4d
AG1478, which, like gefitinib and erlotinib, acts as a specific inhibitor of the EGFR tyrosine kinase, has been shown to result in a dose-dependent up-regula-tion of p27KIP1and in hypophosphorylation of the RB protein in human epidermoid carcinoma cell line A431 cells [56] These changes are temporally associated with recruitment of tumor cells in the G1 phase and a marked reduction in the proportion of cells in the S phase The G1 arrest and up-regulation of p27KIP1 resulting from EGFR blockade are caused by the interruption of PI3K signals In addition to p27KIP1, p21WAF1⁄ CIP1 is involved in gefitinib-induced growth inhibition in HNSCC [58] Another group of cell-cycle regulatory molecules – those of the INK4 family – has also been implicated in gefitinib-induced inhibition of cell growth Gefitinib up-regulates p15INK4b in human immortalized keratinocyte HaCaT cells and results in
RB hypophosphorylation and G1 arrest [59] More-over, mouse embryo fibroblasts lacking p15INK4b are resistant to the growth-inhibitory effects of gefitinib
As the level of p15INK4b is increased by MEK inhibi-tors, but not by Akt inhibiinhibi-tors, the induction of
Fig 3 The cell-cycle is arrested at the G 1
phase by TKI-induced CDK inhibitors EGFR-TKIs result in the up-regulation of CDK inhib-itors, including KIP family members and INK4 family members Members of the KIP family can inhibit the catalytic activity of CDK2, 4 and 6 Members of the INK4 family are specific inhibitors of the cyclin D–CDK4 ⁄ 6 complex It is not yet known
if EGFR-TKIs can stop G2transition and G 2 ⁄ M cell-cycle progression by up-regulation of KIP family members.
Trang 6p15INK4b by inhibition of the ERK1⁄ 2 pathway is
associated with the antiproliferative effects of gefitinib
Inhibition of cell motility
The EGFR can transmit signals for re-organization of
the cytoskeleton, the formation of lamellipodia,
mem-brane ruffling and changes in cell morphology
Accordingly, dysregulation of the EGFR contributes
to the progression, invasion and maintenance of the
malignant phenotype In keratinocyte and cutaneous
squamous cancer cells, gefitinib blocks EGF-induced
cytoskeleton remodeling and in vitro invasiveness, as
well as cell growth [60] Gefitinib also effectively
inhib-its ERK1⁄ 2 activation and p21-activated kinase 1
(Pak1) activity (see Fig 1) Pak1 is a serine⁄ threonine
kinase and is a critical component of many growth
fac-tor recepfac-tor-mediated signal transduction pathways,
leading to directional cell motility and cell invasiveness
[61] Because deregulation of EGFR signaling is
com-monly associated with stimulation of ERK1⁄ 2 and
Pak1 pathways, gefitinib might lead to inhibition of
invasiveness of human cancer cells through the
inhibi-tion of ERK1⁄ 2 and Pak1 The use of gefitinib in cells
with activated ERK1⁄ 2 or Pak1 pathways might
potentially lead to beneficial anti-cancer activity
through the inhibition of not only cell survival but also
cell invasiveness
p38, JNK and Fas as target molecules
of gefitinib
p38
As described above, the treatment of intestinal
epithe-lial cells with gefitinib results in a dramatic increase in
apoptosis and activation of the intrinsic apoptotic
pathway via trafficking of activated Bax to the
mito-chondria [62] Akt is known to phosphorylate Bax and
to prohibit its mitochondrial translocation However,
the Akt pathway plays a minor role in the induction
of apoptosis in intestinal epithelial cells Instead, p38
MAPK phosphorylation is associated with
mitochon-drial translocation of Bax and subsequent induction of
apoptosis following EGFR inhibition (pathway in
Fig 2) Furthermore, p38a, one of the four p38
iso-forms, is required for Bax activation and apoptosis
Because activation of p38 by UVB irradiation in
human keratinocytes results in induction of a
confor-mational change in Bax and its translocation to
mito-chondria [63], p38 may be an important upstream
molecule of Bax activation in response to a variety of
apoptosis-inducing stimuli
JNK and mitogen-activated protein kinase phosphatase-1
The activity of JNK, one of the MAPKs, is tightly controlled by both protein kinases, such as MAPK kinase 4 (MKK4) or MAPK kinase 7 (MKK7) and protein phosphatases such as MAPK phosphatase (MKP) Mitogen-activated protein kinase
phosphatase-1 (MKP-phosphatase-1) is a dual-specificity protein phosphatase, which can dephosphorylate both phosphothreonine and phosphotyrosine residues and subsequently block the activities of MAPKs [64] Although MKP-1 was initially characterized as an ERK-specific phosphatase [65], subsequent studies have determined that MKP-1 preferentially acts on JNK and p38 MAPK in response
to various stresses [66]
MKP-1 has been correlated with tumorigenesis Several observations have indicated that MKP-1 is overexpressed in human tumors Constitutive expression levels of MKP-1 in NSCLC cell lines are higher than those found in normal cells under basal growth condi-tions [67] Overexpression of MKP-1 has been reported
to protect cells against apoptosis induced by UV irradia-tion, Fas ligand, cisplatin, paclitaxel, proteasome inhibi-tors or radiation therapy [68] These observations have established that MKP-1 plays an important role in resistance against many types of stresses, including anti-cancer drugs, in various cell lines MKP-1 may be a rational target to enhance anticancer drug activity Our recent results have shown that the activation of JNK induced by EGFR-TKI AG1478 is critical for the apoptotic action of AG1478 against the NSCLC cell line PC-9 [69] Various types of stimuli activate JNK through phosphorylation by the dual-specificity JNK kinases; but JNK kinases MKK4 and MKK7 are not activated by AG1478 treatment In contrast, JNK phosphatase (i.e MKP-1) is constitutively expressed in PC-9 cells and its expression level is reduced by AG1478 Furthermore, the inhibition of JNK activation by ectopic expression of MKP-1 or a domi-nant-negative form of JNK strongly suppresses AG1478-induced apoptosis Thus, JNK, which is acti-vated through the decrease in the MKP-1 level, is criti-cal for the apoptotic action of AG1478 against PC-9 cells Interestingly, AG1478 has no inhibitory activity towards MKP-1 expression in some resistant cell lines isolated from gefitinib-sensitive PC-9 cells (unpublished data of T Shin-ya, K Takeuchi and F Ito)
Although MKP-1 expression has been implicated in cancer and in TKI sensitivity, the mechanism by which EGFR activation controls the MKP-1 expression level
is unclear MKP-1 is encoded by an early response gene, which is transiently induced by mitogens and
Trang 7stress signals such as serum, growth factors, cytokines,
UV irradiation, heat shock, hypoxia and anticancer
drugs [68] through both transcriptional [70,71] and
post-translational [72,73] mechanisms As depicted in
Fig 3, the human mkp-1 gene contains four exons and
three introns coding for an inducible mRNA that is
approximately 2.4 kb long [74] The
pro-moter⁄ enhancer region of the mkp-1 gene contains
multiple activator protein 2 (AP2), trans-acting
tran-scription factor 1 (SP1) and cAMP-response element
(CRE) sites, but only one site for each of activator
protein 1 (AP1), neurofibromin 1 (NF1) and TATA
box [74] ERK1⁄ 2 can phosphorylate Ser133 of the
CRE-binding protein (CREB) through p90Rsk-2, and
Ser133 phosphorylation is required for
CREB-medi-ated transcription [75] These results suggest that
EGFR signaling can induce the transcription of mkp-1
via phosphorylation of CREB However, induction of
MKP-1 in mouse embryo fibroblasts following
treat-ment with arsenite and irradiation with UVC is
pre-dominantly mediated by the p38 MAPK pathway
Both p38 MAPK and ERK have been implicated in
the transcriptional induction of MKP-1, and each may
use a different set of transcription factors to enhance
MKP-1 expression
Several lines of evidence suggest that
phosphoryla-tion of MKP-1 protein plays an important role in the
stabilization of MKP-1 (Fig 4) ERK1⁄ 2 reduces
MKP-1 degradation by phosphorylating the Ser359
and Ser364 residues of MKP-1 [72] ERK1⁄ 2 is also
responsible for the degradation of MKP-1 via the
phosphorylation of Ser296 and Ser323 residues [76]
Once phosphorylated, Skp2 (also called SCFSkp2 of
Skp1⁄ Cul1 ⁄ F-box protein Skp2; ubiquitin-protein
iso-peptide ligase E3) targets MKP-1 for degradation via
the ubiquitin proteasomal pathway [73] In addition to the transcriptional and post-translational control described here, it is suggested that transcription of the mkp-1 gene is also controlled at the level of transcrip-tional elongation [71] The mechanism responsible for the regulation of MKP-1 expression is complex, and both transcriptional down-regulation and degradation
of MKP-1 may be effects observed in cells having an apoptotic response to EGFR-TKI AG1478
Fas Exposure of the human NSCLC cell line, A549, to gef-itinib causes a marked increase in the expression of Fas protein and in the activation of caspases 2, 3 and
8 [77] Co-treatment of cells with Fas antagonist anti-body significantly blocks gefitinib-induced apoptosis Furthermore, caspase-8 and caspase-3 inhibitors, but not a caspase-9 inhibitor, are capable of restoring cell viability Thus, Fas appears to play a major role in the initiation of gefitinib-induced apoptosis through activa-tion of the caspase-8⁄ caspase-3 cascade Treatment of A549 cells with gefitinib results in the translocation of p53 from the cytosol to the nucleus Moreover, inhibi-tion of p53 using antisense oligonucleotide causes down-regulation of Fas and a significant decrease in gefitinib-induced apoptosis p53 may thus play a role
in determining gefitinib sensitivity by regulating Fas expression in NSCLC
Conclusions
Important regulators of cell survival and apoptosis are the Bcl-2 family of proteins Members of this family, such as Bcl-2 and Bcl-xL, can inhibit apoptosis,
Fig 4 Regulation of MKP-1 expression by EGFR signaling MKP-1 expression is controlled through both transcription and post-translation steps ERK1 ⁄ 2, JNK and p38 MAPK can activate transcription of the mkp-1 gene The promoter ⁄ enhancer region
of the mkp-1 gene has the potential to bind many transcription factors AP1, activator protein 1; CAD, phosphatase catalytic domain; CRE, cAMP-responsive element; NF1, neurofibromin 1; SP1, trans-acting transcription factor 1.
Trang 8whereas others promote apoptosis The balance
between these pro-apoptotic and anti-apoptotic Bcl-2
family members determines the cellular fate (i.e
survival or apoptosis) In cancer cells that undergo
apoptosis in response to TKIs, shutdown of ERK1⁄ 2
and PI3K⁄ Akt signaling pathways following the
inhi-bition of EGFR activation ultimately results in the
disruption of the balance between pro-apoptotic and
anti-apoptotic Bcl-2 proteins and subsequent
apopto-sis Bcl-2 family proteins are key molecules for
regulat-ing the permeabilization of the outer mitochondrial
membrane and thus represent pivotal components in
TKI-dependent apoptosis signaling TKIs change the
transcription level of Bcl-2 family genes and the
phos-phorylation state of their proteins, thereby changing
the amount and localization of Bcl-2 family members
However, each type of cancer has its own way of
disrupting the balance of the networks of signaling
cascades following TKI treatment Therefore,
under-standing how Bcl-2 family members are regulated in
each type of cancer is critical for understanding how
TKIs cause apoptosis in each of them
It is now clear that TKIs are unlikely to provide
cures for the majority of patients with NSCLC
Despite the initial dramatic efficacy of gefitinib and
erlotinib in NSCLC patients with EGFR mutations,
all patients ultimately develop resistance to TKIs A
secondary mutation in the EGFR (T790M) and the
amplification of hepatocyte growth factor receptors
have been identified as major mechanisms of acquired
resistance to TKIs [78] However, it is still important
to identify additional mechanisms of resistance and to
overcome acquired resistance to TKIs Research on
the signaling routes from the EGFR to Bcl-2 family
members will provide critical information to augment
the efficacy of TKIs and to identify patients who will
have a positive response to TKIs
Acknowledgements
This work was supported, in part, by a grant-in-aid
for scientific research from the Ministry of Education,
Culture, Sports, Science, and Technology of Japan,
and by funding from the Fugaku Trust for Medical
Research
References
1 Burgess AW, Cho HS, Eigenbrot C, Ferguson KM,
Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX,
Ward CW & Yokoyama S (2003) An open-and-shut
case? Recent insights into the activation of EGF⁄ ErbB
receptors Mol Cell 12, 541–552
2 Citri A & Yarden Y (2006) EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7, 505–516
3 Mendelsohn J & Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21, 2787–2799
4 Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao
W & Varmus HE (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors Genes Dev 20, 1496–1510
5 Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R et al (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell
9, 485–495
6 Herbst RS & Bunn PA Jr (2003) Targeting the epidermal growth factor receptor in non-small cell lung cancer Clin Cancer Res 9, 5813–5824
7 Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamam-oto N, YamamYamam-oto N, Takeda K, Swaisland H, Naka-tani I, Hirose M et al (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor recep-tor tyrosine kinase inhibirecep-tor gefitinib (‘Iressa’, ZD1839)
in Japanese patients with solid malignant tumors Ann Oncol 14, 922–930
8 Gazdar AF, Shigematsu H, Herz J & Minna JD (2004) Mutations and addiction to EGFR: the Achilles ‘heal’
of lung cancers? Trends Mol Med 10, 481–486
9 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating muta-tions in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
N Engl J Med 350, 2129–2139
10 Paez JG, Ja¨nne PA, Lee JC, Tracy S, Greulich H, Gab-riel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ
et al.(2004) EGFR mutations in lung cancer: correla-tion with clinical response to gefitinib therapy Science
304, 1497–1500
11 Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L et al (2004) EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101, 13306–13311
12 Janmaat ML, Kruyt FA, Rodriguez JA & Giaccone G (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9, 2316–2326
Trang 913 del Peso L, Gonzalez-Garcia M, Page C, Herrera R &
Nunez G (1997) Interleukin-3-induced phosphorylation
of BAD through the protein kinase Akt Science 278,
687–689
14 Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu
LS, Anderson MJ, Arden KC, Blenis J & Greenberg
ME (1999) Akt promotes cell survival by
phosphorylat-ing and inhibitphosphorylat-ing a Forkhead transcription factor Cell
96, 857–868
15 Marte BM & Downward J (1997) PKB⁄ Akt: connecting
phosphoinositide 3-kinase to cell survival and beyond
Trends Biochem Sci 22, 355–358
16 Cardone MH, Roy N, Stennicke HR, Salvesen GS,
Franke TF, Stanbridge E, Frisch S & Reed JC (1998)
Regulation of cell death protease caspase-9 by
phos-phorylation Science 282, 1318–1321
17 Takeuchi K & Ito F (2004) Suppression of
adriamycin-induced apoptosis by sustained activation of the
phos-phatidylinositol-3¢-OH kinase-Akt pathway J Biol
Chem 279, 892–900
18 Engelman JA, Ja¨nne PA, Mermel C, Pearlberg J,
Mukohara T, Fleet C, Cichowski K, Johnson BE &
Cantley LC (2005) ErbB-3 mediates phosphoinositide
3-kinase activity in gefitinib-sensitive non-small cell lung
cancer cell lines Proc Natl Acad Sci USA 102,
3788–3793
19 Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S,
Kinoshita H, Fujii T & Kuwano M (2004) Sensitivity to
gefitinib (Iressa, ZD1839) in non-small cell lung cancer
cell lines correlates with dependence on the epidermal
growth factor (EGF) receptor⁄ extracellular
signal-regu-lated kinase 1⁄ 2 and EGF receptor ⁄ Akt pathway for
proliferation Mol Cancer Ther 3, 465–472
20 Green DR & Kroemer G (2004) The pathophysiology
of mitochondrial cell death Science 305, 626–629
21 Chipuk JE, Bouchier-Hayes L & Green DR (2006)
Mitochondrial outer membrane permeabilization during
apoptosis: the innocent bystander scenario Cell Death
Differ 13, 1396–1402
22 Strasser A, O’Connor L & Dixit VM (2000) Apoptosis
signaling Annu Rev Biochem 69, 217–245
23 Huang DCS & Strasser A (2000) BH3-only proteins –
essential initiators of apoptotic cell death Cell 103,
839–842
24 Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC,
Cowan CW, Dikkes P, Korsmeyer SJ & Greenberg ME
(2002) Survival factor-mediated BAD phosphorylation
raises the mitochondrial threshold for apoptosis Dev
Cell 3, 631–643
25 Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh
Y & Greenberg ME (1997) Akt phosphorylation of
BAD couples survival signals to the cell-intrinsic death
machinery Cell 91, 231–241
26 Bonni A, Brunet A, West AE, Datta SR, Takasu MA
& Greenberg ME (1999) Cell survival promoted by the
Ras-MAPK signaling pathway by transcription-depen-dent and -indepentranscription-depen-dent mechanisms Science 286, 1358– 1362
27 Shimamura A, Ballif BA, Richards SA & Blenis J (2000) Rsk1 mediates a MEK-MAP kinase cell survival signal Curr Biol 10, 127–135
28 Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O’Hare MJ, Wakeling A, Korsmeyer SJ & Streuli CH (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor
J Biol Chem 277, 27643–27650
29 Nakano K & Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53 Mol Cell 7, 683– 694
30 Yu J, Zhang L, Hwang PM, Kinzler KW & Vogelstein
B (2001) PUMA induces the rapid apoptosis of colorec-tal cancer cells Mol Cell 7, 673–682
31 Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle
JN et al (2003) Puma is an essential mediator of p53-dependent and -independent apoptotic pathways Cancer Cell 4, 321–328
32 Yu J & Zhang L (2003) No PUMA, no death: implica-tions for p53-dependent apoptosis Cancer Cell 4, 248– 249
33 Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L & Yu J (2009) PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells Oncogene 28, 2348–2357
34 O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, Cory S & Huang DC (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis EMBO J 17, 384–395
35 Puthalakath H, Huang DC, O’Reilly LA, King SM & Strasser A (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex Mol Cell 3, 287–296
36 Marani M, Tenev T, Hancock D, Downward J & Lemoine NR (2002) Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis Mol Cell Biol 22, 3577–3589
37 Ley R, Balmanno K, Hadfield K, Weston C & Cook SJ (2003) Activation of the ERK1⁄ 2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim J Biol Chem
278, 18811–18816
38 Costa DB, Halmos B, Kumar A, Schumer ST, Huber-man MS, Boggon TJ, Tenen DG & Kobayashi S (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR muta-tions PLoS Med 4, 1669–1679
39 Cragg MS, Kuroda J, Puthalakath H, Huang DC & Strasser A (2007) Gefitinib-induced killing of NSCLC
Trang 10cell lines expressing mutant EGFR requires BIM and
can be enhanced by BH3 mimetics PLoS Med 4, 1681–
1689
40 Gong Y, Somwar R, Politi K, Balak M, Chmielecki J,
Jiang X & Pao W (2007) Induction of BIM is essential
for apoptosis triggered by EGFR kinase inhibitors in
mutant EGFR-dependent lung adenocarcinomas PLoS
Med 4, 1655–1668
41 Xiang J, Chao DT & Korsmeyer SJ (1996)
BAX-induced cell death may not require interleukin 1
beta-converting enzyme-like proteases Proc Natl Acad Sci
USA 93, 14559–14563
42 Meijerink JP, Mensink EJ, Wang K, Sedlak TW,
Sloetjes AW, de Witte T, Waksman G & Korsmeyer SJ
(1998) Hematopoietic malignancies demonstrate
loss-of-function mutations of BAX Blood 91, 2991–2997
43 Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG
& Youle RJ (1997) Movement of Bax from the cytosol
to mitochondria during apoptosis J Cell Biol 139,
1281–1292
44 Ju¨rgensmeier JM, Xie Z, Deveraux Q, Ellerby L,
Bredesen D & Reed JC (1998) Bax directly induces
release of cytochrome c from isolated mitochondria
Proc Natl Acad Sci USA 95, 4997–5002
45 Tsuruta F, Masuyama N & Gotoh Y (2002) The
phosphatidylinositol 3-kinase (PI3K)-Akt pathway
suppresses Bax translocation to mitochondria J Biol
Chem 277, 14040–14047
46 Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB,
Frasch SC, Borregaard N, Marrack P, Bratton DL &
Henson PM (2004) Phosphorylation of Bax Ser184 by
Akt regulates its activity and apoptosis in neutrophils
J Biol Chem 279, 21085–21095
47 Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K,
Harada M & Nakano S (2006) Gefitinib, a selective
EGFR tyrosine kinase inhibitor, induces apoptosis
through activation of Bax in human gallbladder
adeno-carcinoma cells J Cell Biochem 97, 724–734
48 Yanase N, Ohshima K, Ikegami H & Mizuguchi J
(2000) Cytochrome c release, mitochondrial membrane
depolarization, caspase-3 activation, and Bax-alpha
cleavage during IFN-alpha-induced apoptosis in Daudi
B lymphoma cells J Interferon Cytokine Res 20, 1121–
1129
49 Wood DE & Newcomb EW (2000) Cleavage of Bax
enhances its cell death function Exp Cell Res 256, 375–
382
50 Gao G & Dou QP (2000) N-terminal cleavage of bax
by calpain generates a potent proapoptotic 18-kDa
frag-ment that promotes bcl-2-independent cytochrome C
release and apoptotic cell death J Cell Biochem 80,
53–72
51 Toyota H, Yanase N, Yoshimoto T, Moriyama M,
Sudo T & Mizuguchi J (2003) Calpain-induced
Bax-cleavage product is a more potent inducer of
apoptotic cell death than wild-type Bax Cancer Lett
189, 221–230
52 Peng XH, Cao ZH, Xia JT, Carlson GW, Lewis MM, Wood WC & Yang L (2005) Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research Cancer Res
65, 1909–1917
53 Liu Z, Li H, Derouet M, Filmus J, LaCasse EC, Korneluk RG, Kerbel RS & Rosen KV (2005) ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation J Biol Chem 280, 37383–37392
54 Takaoka S, Iwase M, Uchida M, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M & Shintani S (2007) Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells Int J Oncol 30, 1469–1476
55 Ciardiello F & Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7, 2958–2970
56 Busse D, Doughty RS, Ramsey TT, Russell WE, Price
JO, Flanagan WM, Shawver LK & Arteaga CL (2000) Reversible G(1) arrest induced by inhibition of the epi-dermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity J Biol Chem 275, 6987–6995
57 Massague J (2004) G1cell-cycle control and cancer Nature 432, 298–306
58 Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo
S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S et al (2003) Critical role of both p27KIP1 and p21CIP1⁄ WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells J Cell Physiol 195, 139–150
59 Koyama M, Matsuzaki Y, Yogosawa S, Hitomi T, Kawanaka M & Sakai T (2007) ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mito-gen-activated protein kinase⁄ extracellular signal-regu-lated kinase pathway Mol Cancer Ther 6, 1579–1587
60 Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK & Kumar R (2003) Suppres-sion of epidermal growth factor receptor, mitogen-acti-vated protein kinase, and Pak1 pathways and
invasiveness of human cutaneous squamous cancer cells
by the tyrosine kinase inhibitor ZD1839 (Iressa) Mol Cancer Ther 2, 345–351
61 Adam L, Vadlamudi R, Mandal M, Chernoff J & Kumar R (2000) Regulation of microfilament reorgani-zation and invasiveness of breast cancer cells by p21-activated kinase-1 K299R J Biol Chem 275, 12041– 12050